Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with liver tumors, either starting in the liver or spreading there from elsewhere in the body (any tumor type).
• People for whom a liver treatment called radioembolization (a procedure that delivers radiation directly to liver tumors through blood vessels) has been recommended by their doctor.
• People whose liver tumors are at least 2 cm in size.
• People aged 18 or older.
• People who are able to make their own medical decisions and give consent without a legal representative acting on their behalf.
• People who are willing and able to sign a written consent form.

Who may not be able to join:

• People with a serious health condition that would make it unsafe to receive a blood pressure medication called angiotensin II, including: high blood pressure that is not being controlled, currently taking three or more blood pressure-lowering medications, or having had a stroke, other blood vessel blockage, or blood clot in the past 6 months.
• People currently taking a type of blood pressure medication known as ACE inhibitors (such as ramipril or perindopril).
• People currently taking a type of blood pressure medication known as ARBs (such as irbesartan or candesartan).
• People who have a known condition that causes their blood to clot too easily (sometimes called thrombophilia).
• People with a history of serious disease affecting the blood vessels in the arms or legs (peripheral vascular disease).
• People with a known allergy to angiotensin II, which is the active ingredient in the medication Giapreza used in this trial.
• People with a known allergy to any other ingredients in Giapreza, including mannitol, sodium hydroxide, or hydrochloric acid.
• People with a serious or long-term liver disease that would make the radioembolization procedure unsafe.
• People where pre-treatment scans show that the radiation would spread to areas outside the liver in a way that cannot be corrected (some limited spread to specific nearby structures is accepted — confirm with trial site).
• People who are pregnant or breastfeeding.
• People who weigh more than 150 kg, due to the weight limit of the procedure table.
• People with a known severe allergy to the contrast fluid (dye) used in intravenous scans.
• People already taking part in another clinical research study that could affect the results of this trial.
• People with any other significant health condition that may make the radioembolization procedure unsafe.

Important: Always verify eligibility with the trial site directly before applying.